lncRNAANRIL在胶质瘤组织中的表达及其临床意义

Expression and clinical significance of lncRNAANRIL in glioma tissues

目的:探讨lnc RNAANRIL在胶质瘤患者组织标本中的表达及其临床意义。方法:收集2012年1月1日至2016年12月30日于四川省人民医院就诊的临床资料完整的129例胶质瘤患者肿瘤组织及25例对照正常脑组织标本,应用Real-time PCR检测lnc RNAANRIL的表达水平,分析其表达与患者对替莫唑胺的敏感性及临床预后的关系。结果:与对照组脑组织标本比较,lnc RNA ANRIL在129例胶质瘤组织中的表达明显升高[(8.730±0.336)vs(1.090±0.137),t=9.957、P<0.01],在WHO分级Ⅰ~Ⅱ级患者中的表达明显低于Ⅲ~Ⅳ级[(4.198±0.260)vs(10.550±0.291),t=13.03、P<0.01],lnc RNAANRIL的表达与患者的年龄、性别、术前KPS评分、肿瘤直径无关(均P>0.05),与肿瘤WHO分级、对替莫唑胺的敏感性及生存状态明显相关(均P<0.05)。低表达lnc RNA ANRIL患者的总生存时间较高表达者明显延长[(29.17±0.64)vs(13.54±0.74)个月,P<0.01],低表达lnc RNA ANRIL患者的无复发生存时间较高表达者明显延长[(15.88±0.83)vs(9.08±0.56)个月,P<0.01]。单因素及Cox多因素回归模型分析提示,lnc RNA ANRIL的表达、WHO分级及对替莫唑胺的敏感性是胶质瘤独立的预后因素(P<0.05)。结论:胶质瘤患者的肿瘤病理级别越高,lnc RNA ANRIL的表达越高,患者生存时间越短。lnc RNA ANRIL参与调节胶质瘤的发生发展,可作为胶质瘤诊断和预后评估潜在的分子标志物。

Objective： To investigate the expression and clinical significance of lnc RNA ANRIL in glioma tissues. Methods： 129 cases of glioma tissues and 25 cases of normal brain tissues as control were collected from patients treated in Sichuan Provincial People＇s Hospital from January 01, 2012 to December 30, 2016. Real-time quantitative PCR was used to detect the mRNA expression of lnc RNA ANRIL; and the relationship between lnc RNA ANRIL expression and sensitivity of patients to temozolomide as well as the clinical prognosis of glioma patients were analyzed. Results： Compared with control group, the expression of lnc RNA ANRIL in 129 cases of glioma tissues was significantly increased（[8.730±0.336] vs [1.090±0.137], t=9.957, P〈0.01）. The expression of lnc RNA ANRIL in WHO Ⅰ-Ⅱ grade patients was significantly lower than that of patients at grade Ⅲ-Ⅳ（[4.198±0.260] vs [10.550±0.291], t=13.03, P〈0.01）. lnc RNA ANRIL expression was significantly correlated with WHO stage,the sensitivity to temozolomide（TMZ）and survival status（all P〈0.05）, but not associated with gender, age, KPS score and tumor size（all P〈0.05）. Moreover, Kaplan-Meier analysis demonstrated that decreased lnc RNA ANRIL expression contributed to significantly longer overall survival（[29.17±0.64] vs [13.54±0.74]months, P〈0.01） and recurrence-free survival time（[9.08±0.56] vs [15.88±0.83] months, P〈0.01）. Univariate and multivariate analysis also indicated that lnc RNA ANRIL expression, WHO stage and chemosensitivity could be independent prognostic markers for glioma（P〈0.05）. Conclusion： Higher pathological grade of glioma patients indicates higher lnc RNA ANRIL expression and shorter survival time. lnc RNA ANRIL is involved in the occurrence and development of glioma, and can be used as a molecular marker for the diagnosis and prognosis of glioma.